The role of levosimendan in acute heart failure complicating acute coronary syndrome: A review and expert consensus opinion Nieminen,

[1]  V. Harjola,et al.  Acute Heart Failure , 2018, Update in Intensive Care and Emergency Medicine.

[2]  J. Parissis,et al.  Levosimendan meta-analyses: Is there a pattern in the effect on mortality? , 2016, International journal of cardiology.

[3]  J. Papp,et al.  Calcium sensitizers: What have we learned over the last 25 years? , 2016, International journal of cardiology.

[4]  J. Knuuti,et al.  Effect of levosimendan therapy on myocardial infarct size and left ventricular function after acute coronary occlusion , 2016, Heart.

[5]  K. Sliwa,et al.  Acute heart failure and cardiogenic shock: a multidisciplinary practical guidance , 2016, Intensive Care Medicine.

[6]  S. de Servi,et al.  Temporal trends in the epidemiology, management, and outcome of patients with cardiogenic shock complicating acute coronary syndromes , 2015, European journal of heart failure.

[7]  E. Ohman,et al.  Management of cardiogenic shock. , 2015, European heart journal.

[8]  Holger Thiele,et al.  Clinical picture and risk prediction of short‐term mortality in cardiogenic shock , 2015, European journal of heart failure.

[9]  T. Jernberg,et al.  Incidence, temporal trends, and prognostic impact of heart failure complicating acute myocardial infarction. The SWEDEHEART Registry (Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies): a study of 199,851 patients , 2015, JACC. Heart failure.

[10]  J. Zijlstra,et al.  Effects of levosimendan for low cardiac output syndrome in critically ill patients: systematic review with meta-analysis and trial sequential analysis , 2015, Intensive Care Medicine.

[11]  M. Nieminen,et al.  Acute heart failure with and without concomitant acute coronary syndromes: patient characteristics, management, and survival. , 2014, Journal of cardiac failure.

[12]  C. Selzman,et al.  Pharmacologic therapies for acute cardiogenic shock , 2014, Current opinion in cardiology.

[13]  Yanzhou Zhang,et al.  Enhancement of Myocardial Function and Reduction of Injury with Levosimendan after Percutaneous Coronary Intervention for Acute Myocardial Infarction: A Pilot Study , 2014, Cardiology.

[14]  Li-Yuan Zhang,et al.  Efficacy of Intravenous Levosimendan in Patients with Heart Failure Complicated by Acute Myocardial Infarction , 2014, Cardiology.

[15]  J. Haerting,et al.  Inotropic agents and vasodilator strategies for acute myocardial infarction complicated by cardiogenic shock or low cardiac output syndrome. , 2014, The Cochrane database of systematic reviews.

[16]  B. Power.  Faculty Opinions recommendation of High levels of circulating epinephrine trigger apical cardiodepression in a β2-adrenergic receptor/Gi-dependent manner: a new model of Takotsubo cardiomyopathy. , 2013 .

[17]  N. Brunetti,et al.  Safety and feasibility of levosimendan administration in takotsubo cardiomyopathy: a case series. , 2013, Cardiovascular therapeutics.

[18]  S. Ricksten,et al.  Effects of Levosimendan on Glomerular Filtration Rate, Renal Blood Flow, and Renal Oxygenation After Cardiac Surgery With Cardiopulmonary Bypass: A Randomized Placebo-Controlled Study* , 2013, Critical care medicine.

[19]  A. Mebazaa,et al.  The Effectiveness of Inodilators in Reducing Short Term Mortality among Patient with Severe Cardiogenic Shock: A Propensity-Based Analysis , 2013, PloS one.

[20]  A. Parkhomenko,et al.  Renal Effects of Levosimendan: A Consensus Report , 2013, Cardiovascular Drugs and Therapy.

[21]  G. Andersen,et al.  Levosimendan in acute heart failure following primary percutaneous coronary intervention‐treated acute ST‐elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo‐controlled study , 2013, European journal of heart failure.

[22]  J. Chirinos.  Ventricular-arterial coupling: Invasive and non-invasive assessment. , 2012, Artery research.

[23]  A. Parkhomenko,et al.  Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. , 2012, International journal of cardiology.

[24]  N. Peters,et al.  High Levels of Circulating Epinephrine Trigger Apical Cardiodepression in a &bgr;2-Adrenergic Receptor/Gi–Dependent Manner: A New Model of Takotsubo Cardiomyopathy , 2012, Circulation.

[25]  K. Werdan,et al.  Cardiogenic shock due to myocardial infarction: diagnosis, monitoring and treatment: a German-Austrian S3 Guideline. , 2012, Deutsches Arzteblatt international.

[26]  G. Biondi-Zoccai,et al.  Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies* , 2012, Critical care medicine.

[27]  S. Behar,et al.  Outcomes of acute heart failure associated with acute coronary syndrome versus other causes , 2011, Acute cardiac care.

[28]  R. Porcher,et al.  Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity scoring methods , 2011, Intensive Care Medicine.

[29]  J. Borén,et al.  Levosimendan neither improves nor worsens mortality in patients with cardiogenic shock due to ST-elevation myocardial infarction , 2010, Vascular health and risk management.

[30]  R. Strasser,et al.  Postconditioning with levosimendan reduces the infarct size involving the PI3K pathway and KATP-channel activation but is independent of PDE-III inhibition , 2010, Basic Research in Cardiology.

[31]  J. Sellgren,et al.  Dopamine increases renal oxygenation: a clinical study in post‐cardiac surgery patients , 2010, Acta anaesthesiologica Scandinavica.

[32]  K. Werdan,et al.  Right ventricular function in myocardial infarction complicated by cardiogenic shock: Improvement with levosimendan* , 2009, Critical care medicine.

[33]  A. Cohen-Solal,et al.  Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure. , 2009, Journal of the American College of Cardiology.

[34]  M. Pfisterer,et al.  Ten-Year Trends in the Incidence and Treatment of Cardiogenic Shock , 2008, Annals of Internal Medicine.

[35]  Edward G Lakatta,et al.  Arterial-ventricular coupling: mechanistic insights into cardiovascular performance at rest and during exercise. , 2008, Journal of applied physiology.

[36]  A. Domínguez-Rodríguez,et al.  Effects of levosimendan versus dobutamine on left ventricular diastolic function in patients with cardiogenic shock after primary angioplasty. , 2008, International journal of cardiology.

[37]  R. Strasser,et al.  Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction* , 2008, Critical care medicine.

[38]  A. Domínguez-Rodríguez,et al.  Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. , 2008, International journal of cardiology.

[39]  L. Opie,et al.  A role for the RISK pathway and KATP channels in pre‐ and post‐conditioning induced by levosimendan in the isolated guinea pig heart , 2008, British journal of pharmacology.

[40]  K. Werdan,et al.  Early and sustained haemodynamic improvement with levosimendan compared to intraaortic balloon counterpulsation (IABP) in cardiogenic shock complicating acute myocardial infarction , 2008, Acute cardiac care.

[41]  K. Werdan,et al.  Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock * , 2007, Critical care medicine.

[42]  A. Terzic,et al.  ATP-sensitive potassium channels: metabolic sensing and cardioprotection. , 2007, Journal of applied physiology.

[43]  M. Bunc,et al.  Levosimendan improves renal function in patients with advanced chronic heart failure awaiting cardiac transplantation. , 2007, Journal of cardiac failure.

[44]  A. Cohen-Solal,et al.  Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. , 2007, JAMA.

[45]  E. Vahtola,et al.  Effects of levosimendan on cardiac remodeling and cardiomyocyte apoptosis in hypertensive Dahl/Rapp rats , 2007, British journal of pharmacology.

[46]  A. Domínguez-Rodríguez,et al.  Cardiogenic shock after primary percutaneous coronary intervention: Effects of levosimendan compared with dobutamine on haemodynamics , 2006, European journal of heart failure.

[47]  P. Ponikowski,et al.  EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. , 2006, European heart journal.

[48]  F. Fedele,et al.  Effects of levosimendan on left ventricular diastolic function after primary angioplasty for acute anterior myocardial infarction: a Doppler echocardiographic study. , 2006, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[49]  Luigi Tavazzi,et al.  Acute Heart Failure Syndromes: Current State and Framework for Future Research , 2005, Circulation.

[50]  W. Colucci,et al.  Cardioprotection: a new paradigm in the management of acute heart failure syndromes. , 2005, The American journal of cardiology.

[51]  F. Fedele,et al.  Levosimendan improves hemodynamics and coronary flow reserve after percutaneous coronary intervention in patients with acute myocardial infarction and left ventricular dysfunction. , 2005, American heart journal.

[52]  L. Lehtonen,et al.  The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. , 2004, Journal of the American College of Cardiology.

[53]  P. Kaheinen,et al.  Effects of Levosimendan and Milrinone on Oxygen Consumption in Isolated Guinea-Pig Heart , 2004, Journal of cardiovascular pharmacology.

[54]  Werner Klein,et al.  Medical Practice Guidelines. Separating science from economics. , 2003, European heart journal.

[55]  J. Hochman,et al.  Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. , 2003, Circulation.

[56]  V. Moiseyev,et al.  Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. a randomized, placebo-controlled, double-blind study (RUSSLAN) , 2003 .

[57]  M. Nieminen,et al.  Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). , 2002, European heart journal.

[58]  P. Kaheinen,et al.  Improved survival with simendan after experimental myocardial infarction in rats. , 2001, European journal of pharmacology.

[59]  H. Iida,et al.  Myocardial efficiency during levosimendan infusion in congestive heart failure , 2000, Clinical pharmacology and therapeutics.

[60]  K. Någren,et al.  Myocardial efficiency during calcium sensitization with levosimendan: A noninvasive study with positron emission tomography and echocardiography in healthy volunteers , 1997, Clinical pharmacology and therapeutics.

[61]  P. Pagel,et al.  Influence of levosimendan, pimobendan, and milrinone on the regional distribution of cardiac output in anaesthetized dogs , 1996, British journal of pharmacology.

[62]  G. Diamond,et al.  Correlative classification of clinical and hemodynamic function after acute myocardial infarction. , 1977, The American journal of cardiology.

[63]  Deepak L. Bhatt,et al.  Trends in Coronary Angiography, Revascularization, and Outcomes of Cardiogenic Shock Complicating Non-ST-Elevation Myocardial Infarction. , 2016, The American journal of cardiology.

[64]  M. Nieminen,et al.  Levosimendan: current data, clinical use and future development , 2013, Heart, lung and vessels.

[65]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[66]  F. Di Lisa.  Mitochondrial contribution in the progression of cardiac ischemic injury. , 2001, IUBMB life.